Overview
Cat #: BLP-CC130
Type: Synthetic peptide
Form: Lyophilized Powder
CaV1.2 (CACNA1C) (extracellular) Blocking Peptide (#BLP-CC130) is the original antigen used for immunization during Anti-CaV1.2 (CACNA1C) (extracellular) Antibody (#ACC-130) generation. The blocking peptide binds and ‘blocks’ Anti-CaV1.2 (CACNA1C) (extracellular) primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
Applications: wb, ihc
Application key:
WB- Western blot, IHC- Immunohistochemistry
For research purposes only. not for human use
Applications
Demonstration of Pre-adsorption control
- Western blot analysis of rat brain membranes:1. Anti-CaV1.2 (CACNA1C) (extracellular) Antibody (#ACC-130), (1:200).
2. Anti-CaV1.2 (CACNA1C) (extracellular) Antibody, preincubated with CaV1.2 (CACNA1C) (extracellular) Blocking Peptide (BLP-CC130). - Western blot analysis of mouse TK-1 T-cell lymphoma cell line lysate (lanes 1 and 3) and mouse Neuro-2a neuroblastoma cell line lysate (lanes 2 and 4):1-2. Anti-CaV1.2 (CACNA1C) (extracellular) Antibody (#ACC-130), (1:200).
3-4. Anti-CaV1.2 (CACNA1C) (extracellular) Antibody, preincubated with CaV1.2 (CACNA1C) (extracellular) Blocking Peptide (BLP-CC130). - Western blot analysis of human Caco-2 colon carcinoma cell line lysate (lanes 1 and 3) and human MDA-MB-231 breast carcinoma cell line lysate (lanes 2 and 4):1-2. Anti-CaV1.2 (CACNA1C) (extracellular) Antibody (#ACC-130), (1:200).
3-4. Anti-CaV1.2 (CACNA1C) (extracellular) Antibody, preincubated with CaV1.2 (CACNA1C) (extracellular) Blocking Peptide (BLP-CC130). - Expression of CaV1.2 in rat cerebellumImmunohistochemical staining of perfusion-fixed frozen rat brain sections with Anti-CaV1.2 (CACNA1C) (extracellular) Antibody (#ACC-130), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. CaV1.2 immunoreactivity (green) appears in Purkinje cells (horizontal arrows) and in their dendrites (vertical arrows). B. Pre-incubation of the antibody with CaV1.2 (CACNA1C) (extracellular) Blocking Peptide (BLP-CC130), suppressed staining. Cell nuclei are stained with DAPI (blue). G = granule layer, M = molecular layer.
- Expression of CaV1.2 in mouse cerebellumImmunohistochemical staining of perfusion-fixed frozen mouse brain sections with Anti-CaV1.2 (CACNA1C) (extracellular) Antibody (#ACC-130), (1:300), followed by goat anti-rabbit-AlexaFluor-488. A. CaV1.2 immunoreactivity (green) appears in Purkinje cells (vertical arrows) and in their dendrites (horizontal arrows). B. Pre-incubation of the antibody with CaV1.2 (CACNA1C) (extracellular) Blocking Peptide (BLP-CC130), suppressed staining. Cell nuclei are stained with DAPI (blue). G = granule layer, M = molecular layer.
Properties
Sequence
- Peptide (C)KK(S)APESEPSNSTEGE, corresponding to amino acid residues 1429 – 1444 of mouse CaV1.2 (Accession Q01815).
Accession (Uniprot) Number Q01815
Peptide Confirmation Confirmed by amino acid analysis and mass spectrometry.
Purity >70%
Storage Before Reconstitution Lyophilized powder can be stored intact at room temperature for two weeks. For longer periods, it should be stored at -20°C.
Reconstitution 100 µl double distilled water (DDW).
Concentration After Reconstitution 0.4 mg/ml.
Storage After Reconstitution -20°C.
Antigen Preadsorption Control 1 µg peptide per 1 µg antibody.
Standard Quality Control Of Each Lot Western blot analysis.